Skip to content
EntityQ5161126· pop 12· linked from 146 articles

conivaptan

Sign in to save

Also known as Vaprisol®, YM-087, YM087, 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide, 4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide

Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). Additionally, conivaptan is used for the treatment of syndrome of inappropriate antidiuretic hormone secretion.

Research

281 papers

via PubMed

Wikidata facts

Mass
498.205576
Show 4 more facts
chemical formula
C₃₂H₂₆N₄O₂
canonical SMILES
CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
World Health Organisation international non-proprietary name
conivaptan
Commons category
Conivaptan
Sources (2)

via Wikidata · CC0

~5 min read

Article

7 sections
Contents
  • Medical uses
  • Pharmacology
  • Adverse effects
  • Chemistry
  • History
  • References
  • External links

Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). Additionally, conivaptan is used for the treatment of syndrome of inappropriate antidiuretic hormone secretion.

Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1A and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

Connections

Categories